Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-22	EGP 742.36	-0.77%	578
26-10-21	EGP 748.10	-0.43%	6,731
26-10-20	EGP 751.34	-0.59%	2,516
26-10-19	EGP 755.83	+0.78%	2,678
26-10-18	EGP 750.00	-5.48%	33,486

End-of-day quote Egyptian Exchange

More quotes

End-of-day quote Egyptian Exchange 2026-10-22			5-day change	1st Jan Change
742.36 ^EGP	-0.77%		-6.44%	+112.59%

Oct. 04	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 27	CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million funding	RE

Market Cap	8.75B 158M 141M 130M 118M 222M 14.98B 225M 1.57B 618M 7.85B 594M 581M 24.87B	P/E 2024	14x	P/E 2025	584x
Enterprise Value	9.86B 178M 159M 147M 133M 250M 16.88B 254M 1.77B 697M 8.85B 669M 655M 28.02B	EV / Sales 2024	0.78x	EV / Sales 2025	0.81x
Free-Float	15.13%	Yield 2024	1.54%	Yield 2025	-

Oct. 04	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 27	CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million funding	RE
Aug. 27	Minapharm Group Receives Funding to Advance Bundibugyo Ebolavirus Vaccine Candidate to Clinical Trials	CI
Aug. 17	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Jun. 10	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE
Nov. 30	Minapharm Pharmaceuticals Q3 consol profit egp 16.8 million	RE
Nov. 29	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-14	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-09-14	Minapharm Pharmaceuticals Q2 consol profit EGP 40 million	RE
25-07-27	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-07-27	Minapharm Pharmaceuticals Q1 consol net loss EGP 2 million	RE
25-06-12	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2024	CI

25-07-07	EBRD, Admaius Capital plan to acquire 15%-20% of Egyptian Minapharm Pharmaceuticals	AQ
25-03-26	African Development Bank Approves Eur 15 Million Loan to Boost Biosimilars' Development and Production in Egypt	AQ
23-10-05	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	AQ
23-10-04	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	AQ
23-03-06	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	AQ

MINAPHARM Pharmaceuticals Stock

Stocks

MIPH

EGS380G1C011

Pharmaceuticals

Valuation: MINAPHARM Pharmaceuticals

Chart: MINAPHARM Pharmaceuticals

Latest news: MINAPHARM Pharmaceuticals

Press Releases: MINAPHARM Pharmaceuticals

Quotes and Performance

Price Extremes

Managers and Directors: MINAPHARM Pharmaceuticals

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-0.77%
1 week	-6.44%
Current month	-4.79%
1 month	-15.64%
3 months	-0.58%
6 months	+31.94%
Current year	+112.59%

1 week	686.2	798
1 month	666.66	879
Current year	320.23	1,000
1 year	302.22	1,000
3 years	145	1,000
5 years	101.05	1,000
10 years	45	1,000

Manager	Title	Age	Since
Shaheer Wafeeq Sa'ad Al-Bardissy CEO	Chief Executive Officer	-	-
Wafik El-Bardissy CEO	Chief Executive Officer	-	2010-10-18
Rafiq Raymond DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Wafik El-Bardissy CHM	Chairman	-	2010-10-17
Anwar Nasr Mekhaeel BRD	Director/Board Member	-	2010-10-17
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MINAPHARM PHARMACEUTICALS	-0.77%	-6.44%	+127.59%	+263.94%	158M
ELI LILLY AND COMPANY	+2.83%	+4.40%	+60.84%	+123.50%	1,165B
JOHNSON & JOHNSON	+3.81%	+5.66%	+38.70%	+74.91%	645B
ABBVIE INC.	+0.14%	+0.63%	+24.71%	+95.03%	504B
ROCHE HOLDING AG	-0.50%	+2.80%	+43.52%	+64.09%	380B
MERCK & CO., INC.	-1.76%	+1.41%	+68.06%	+43.41%	363B
NOVARTIS AG	-1.04%	+2.23%	+21.97%	+50.86%	297B
ASTRAZENECA PLC	-2.06%	+2.12%	+1.71%	+25.84%	269B
AMGEN INC.	+2.04%	+3.05%	+51.12%	+60.42%	237B
GILEAD SCIENCES, INC.	+2.36%	-0.11%	+29.42%	+102.04%	195B
Average	-0.27%	+2.19%	+46.76%	+90.41%	405.56B
Weighted average by Cap.	-0.63%	+3.17%	+43.00%	+82.98%

	2024	2025
Net sales	5.66B 102M 91.45M 84.37M 76.65M 144M 9.7B 146M 1.02B 400M 5.08B 385M 376M 16.11B	6.44B 116M 104M 95.89M 87.12M 163M 11.03B 166M 1.16B 455M 5.78B 437M 428M 18.31B
Net income	157M 2.84M 2.54M 2.34M 2.13M 3.99M 269M 4.05M 28.18M 11.1M 141M 10.66M 10.43M 447M	40.22M 727K 649K 599K 544K 1.02M 68.9M 1.04M 7.22M 2.84M 36.1M 2.73M 2.67M 114M
Net Debt	2.6B 46.99M 41.94M 38.7M 35.16M 65.95M 4.45B 66.97M 466M 184M 2.33B 176M 173M 7.39B	1.11B 20.08M 17.92M 16.53M 15.02M 28.18M 1.9B 28.61M 199M 78.46M 996M 75.36M 73.75M 3.16B